We've found
20,707
archived clinical trials in
Gastrointestinal
We've found
20,707
archived clinical trials in
Gastrointestinal
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)
Updated: 1/1/1970
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Status: Archived
Updated: 1/1/1970
Ulimorelin Study of Efficacy and Safety (ULISES 008)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
Status: Archived
Ulimorelin Study of Efficacy and Safety (ULISES 008)
Updated: 1/1/1970
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
Status: Archived
Updated: 1/1/1970
Comparative Study of Biologic Mesh Versus Repair With Component Separation.
Randomized Control Trial of Biologic Mesh (XenMATRIXTM) vs. Component Separation Alone in Contaminated Ventral Hernia Repair:a Pilot Study
Status: Archived
Comparative Study of Biologic Mesh Versus Repair With Component Separation.
Updated: 1/1/1970
Randomized Control Trial of Biologic Mesh (XenMATRIXTM) vs. Component Separation Alone in Contaminated Ventral Hernia Repair:a Pilot Study
Status: Archived
Updated: 1/1/1970
Ulimorelin Study of Efficacy and Safety (ULISES 007)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
Status: Archived
Ulimorelin Study of Efficacy and Safety (ULISES 007)
Updated: 1/1/1970
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
Status: Archived
Updated: 1/1/1970
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.
Status: Archived
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
Updated: 1/1/1970
Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.
Status: Archived
Updated: 1/1/1970
Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation
An Open Label, Non-randomized Dose-escalation Study to Assess Safety and Tolerability of SI-6603 in Patients With Lumbar Disc Herniation (Phase II Study)
Status: Archived
Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation
Updated: 1/1/1970
An Open Label, Non-randomized Dose-escalation Study to Assess Safety and Tolerability of SI-6603 in Patients With Lumbar Disc Herniation (Phase II Study)
Status: Archived
Updated: 1/1/1970
Pharyngocise Dose Response Study
Muscle Preservation and Swallow Function Following Radiotherapy: A Dose Response Study
Status: Archived
Pharyngocise Dose Response Study
Updated: 1/1/1970
Muscle Preservation and Swallow Function Following Radiotherapy: A Dose Response Study
Status: Archived
Updated: 1/1/1970
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon With That in Matched Healthy Control Subjects
Status: Archived
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
Updated: 1/1/1970
An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon With That in Matched Healthy Control Subjects
Status: Archived
Updated: 1/1/1970
Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia
A Double-blind, Randomized, Placebo-controlled, Dual-center Study on the Effect of Healthy Trinity (Retail Label)/Trenev Trio (Professional Label) on Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and Functional Dyspepsia
Status: Archived
Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia
Updated: 1/1/1970
A Double-blind, Randomized, Placebo-controlled, Dual-center Study on the Effect of Healthy Trinity (Retail Label)/Trenev Trio (Professional Label) on Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and Functional Dyspepsia
Status: Archived
Updated: 1/1/1970
Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia
A Double-blind, Randomized, Placebo-controlled, Dual-center Study on the Effect of Healthy Trinity (Retail Label)/Trenev Trio (Professional Label) on Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and Functional Dyspepsia
Status: Archived
Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia
Updated: 1/1/1970
A Double-blind, Randomized, Placebo-controlled, Dual-center Study on the Effect of Healthy Trinity (Retail Label)/Trenev Trio (Professional Label) on Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and Functional Dyspepsia
Status: Archived
Updated: 1/1/1970
The Effect of a Meal on Vitamin D Absorption
Meal Effects on the 25OHD3 Response to Supplemental Vitamin D3
Status: Archived
The Effect of a Meal on Vitamin D Absorption
Updated: 1/1/1970
Meal Effects on the 25OHD3 Response to Supplemental Vitamin D3
Status: Archived
Updated: 1/1/1970